Michael A. Nauck

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen et al. · New England Journal of Medicine · 2016 · 7.3K citations · Full text

Medicine, Endocrinology, Pharmacotherapy +13

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

Silvio E. Inzucchi, Richard M. Bergenstal, John B. Buse et al. · Diabetes Care · 2014 · 3.1K citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.8K citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

Michael A. Nauck, Markus M. Heimesaat, Jens J. Holst et al. · Journal of Clinical Investigation · 1993 · 1.6K citations · Full text

Medicine, Endocrinology, Pharmacology +15

Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes

Michael A. Nauck, F. Stöckmann, R. Ebert et al. · Diabetologia · 1986 · 1.3K citations · Full text

Medicine, Endocrinology, Pharmacology +13